eprintid: 22992
rev_number: 12
eprint_status: archive
userid: 1589
dir: disk0/00/02/29/92
datestamp: 2017-05-29 09:17:50
lastmod: 2024-05-06 13:25:19
status_changed: 2017-05-29 09:17:50
type: article
metadata_visibility: show
creators_name: Lisenko, Katherina
creators_name: Dingeldein, G.
creators_name: Cremer, Martin
creators_name: Kriegsmann, Mark
creators_name: Ho, Anthony D.
creators_name: Rieger, M.
creators_name: Witzens-Harig, Mathias
title: Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma
subjects: ddc-610
divisions: i-910100
divisions: i-912000
abstract: Background: The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients. However, these results were obtained in young low risk patients and a reevaluation in an unselected patient cohort is warranted.   Methods: In this study, we analyzed 80 PMBCL patients treated with a CHOP-based regimen with and without rituximab.   Results: In the non-rituximab cohort 10-year progression free survival (PFS) was 67% and 10-year overall survival (OS) was 72% versus a PFS of 95% and a OS of 92% in the rituximab group, PFS P = 0.001, OS P = 0.023. A subgroup PFS analysis by international prognostic index (IPI) risk revealed that all risk groups benefit from addition of rituximab to induction chemotherapy. In addition, OS probability was higher in the group of non-low risk patients who were treated with rituximab compared to those patients who did not receive rituximab (P = 0.035). In multivariate analysis, only addition of rituximab to induction chemotherapy and reaching complete remission (CR) after first line therapy had a beneficial effect on both PFS and OS, whereas IPI, age, upfront high dose (HD) chemotherapy/autologous blood stem cell transplantation (ABSCT) and rituximab maintenance had no impact on survival.   Conclusions: Our data demonstrate a survival benefit in unselected PMBCL patients treated with CHOP-like induction regimen and additional rituximab independently of the IPI risk score.
date: 2017
publisher: BioMed Central; Springer
id_scheme: DOI
ppn_swb: 1659204852
own_urn: urn:nbn:de:bsz:16-heidok-229927
language: eng
bibsort: LISENKOKATADDITIONOF2017
full_text_status: public
publication: BMC Cancer
volume: 17
number: 359
place_of_pub: London; Berlin; Heidelberg
pagerange: 1-9
issn: 1471-2407
citation:   Lisenko, Katherina ; Dingeldein, G. ; Cremer, Martin ; Kriegsmann, Mark ; Ho, Anthony D. ; Rieger, M. ; Witzens-Harig, Mathias  (2017) Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.  BMC Cancer, 17 (359).  pp. 1-9.  ISSN 1471-2407     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/22992/1/12885_2017_Article_3332.pdf